Skip Ribbon Commands
Skip to main content

Key Milestones

The National Heart Centre Singapore (NHCS) is dedicated to providing optimal care and outcomes through continuous advancement in patient care, education and training, and research

Read our NHCS anniversary books:

Learn more about our annual key milestones:

  • NHCS partners with Medera’s Novoheart to create the world’s first Asian patient-specific miniature human heart model with heart failure, known as “Human Heart-in-a-Jar”. The collaboration will focus on creating the first Asian patient-specific mini-heart models capable of reproducing key features seen in patients that have heart failure with preserved ejection fraction (HFpEF), and pave the way for precision medicine in heart failure.
  • NHCS launches novel research study, INDEPENDENCY Study, to tackle frailty in older adults to delay onset of cardiovascular disease. The study received a $4.7 million grant funding to test real-world solutions across various healthcare settings to bring about evidence-based strategies to improve frailty and heart health of seniors. A key novelty of the study is a specially curated meal plan and specialised exercise programme, for suitable cardiac frail patients.
  • SingHealth announced a key leadership change at NHCS, with Professor Yeo Khung Keong succeeding the role of CEO, from Professor Terrance Chua.
  • NHCS celebrated its 25th anniversary in conjunction with its fourth NHCS Heart To Heart Gala, raising S$1.2 million for needy patients and cardiac health advancement.
  • NHCS performed the implantation of the HeartMate 3 left ventricular assist device (LVAD) in a 14-year-old boy, the youngest person in Singapore with advanced heart failure. NHCS’ comprehensive heart failure programme which provides end-to-end services, has made the care of patients with generational heart disease possible.
  • Scientists at NHCS and Duke-NUS Medical School, together with colleagues in Singapore, China and the USA devised a way to measure the length of a telomere rapidly and precisely. The discovery marks an important advance in the field of ageing research, especially in the understanding of clinical diseases associated with ageing such as cardiovascular disease. The study was published in Nature Communications.
  • In a world first, scientists at NHCS, Duke-NUS Medical School, and colleagues in Germany discovered a potential regenerative therapy by blocking a damaging and scar-regulating protein called interleukin-11 (IL-11), to restore impaired kidney function. The study was published in Nature Communications.
  • A study led by NHCS discovered a link between the weakening of skeletal muscle function (sarcopenia) and the heart, among older adults within the community population. The significant finding could help in early identification of elderly who are at risk of heart disease and provide insights on geriatric care management for Singapore’s ageing population.
  • A team of researchers from NHCS, Nanyang Technological University, Singapore (NTU Singapore), and Ngee Ann Polytechnic, Singapore (NP), invented a tool powered by AI that could speed up the diagnosis of cardiovascular diseases. The innovation uses electrocardiograms to diagnose coronary artery disease, myocardial infarction and congestive heart failure to an accuracy of more than 98.5 per cent.
  • A global report, the Lancet Commission, urged to reduce the burden of heart disease in women by outlining 10 significant recommendations to improve health outcomes for millions of women by 2030. The Commission is curated by 17 leading expert ambassadors from 11 countries, including Prof Carolyn Lam, the sole representative from Asia.
  • A multinational trial, AFFIRM-AHF, led by researchers from NHCS and international partners has shown that iron therapy significantly reduces re-hospitalisation and provides better health outcomes in patients with heart failure. Research findings have translated into clinical practice in NHCS, as part of the overall treatment strategy for patients with heart failure, for improved patient care.
  • Boehringer Ingelheim partners with Enleofen in a signature biotech deal to research and develop drug therapies, which will help reverse inflammation and fibrosis in diseased organs. Enleofen is a spinout company from NHCS and Duke-NUS Medical School, under the SingHealth Duke-NUS Academic Medical Centre.
  • NHCS launched telemedicine initiatives, including telephone and video consultations, for a wide range of clinical care and services. The telemedicine services are offered to patients with stable conditions, and provides remote care with greater convenience to patients and their caregivers.
  • Researchers from NHCS identified a unique lean diabetic phenotype among Asian patients with heart failure. NHCS researchers together with Asia-wide investigators launched the Asian Diabetes Outcome Prevention Trial (ADOPT), a multinational clinical trial, to help prevent heart diseases in high-risk patients with diabetes.
  • Bayer and NHCS entered into a five-year collaboration agreement to set up a “Center of Excellence for Explorative Cardiovascular Studies”, with the aim of boosting patient-centricity in research and development (R&D) and improving treatment outcomes in cardiovascular disease management.
  • Professor Koh Tian Hai was conferred as an Emeritus Consultant, a first for NHCS.
  • Singapore LIVE (SingLIVE) was successfully concluded from 17 to 18 January 2019. To further strengthen NHCS involvement in this flagship medical event which first began in 1989, SingLIVE was independently organised from 2019, after a decade of joint organisation with Asia PCR.
  • One of NHCS pioneer heart surgeons, Associate Professor Chua Yeow Leng, won the National Outstanding Clinician Award 2019, for his advancement of cardiothoracic surgery standards in NHCS, Singapore and the region, and more.
  • Two newly awarded Clinician Scientists in NHCS – Assistant Professor Calvin Chin and Assistant Professor Angela Koh, who were awarded in the Investigator Category. Organised by National Medical Research Council (NMRC), the prestigious Clinician Scientist award is presented to top researchers who carry out translational and clinical research in Singapore, and help transform patient care with their research.